Pfizer Said Near Allergan Deal as U.S. Targets Inversions

  • U.S. drugmaker may pay as much as $380 per share for Allergan
  • Announcement could be delayed by Treasury inversion plans

Pfizer Said to Be Near Deal for Allergan

Pfizer Inc. is in advanced talks to buy Allergan Plc for as much as $380 per share, according to people familiar with the matter, valuing the Botox maker at as high as $150 billion -- if the U.S. government doesn’t get in the way of the drug industry’s largest-ever deal.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.